kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
78
JPY
0
(0.00%)
Dec 12, 3:30 pm JST
0.50
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
76.7
Dec 12, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.24
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
83 JPY 0.53 USD
Previous Close Dec 11
78 JPY 0.49 USD
High Dec 12, 9:09 am
97 JPY 0.62 USD
Low Dec 12, 12:34 pm
75 JPY 0.48 USD
Volume
12,027,000
Trading Value
1.02B JPY 6.57M USD
VWAP
85.17 JPY 0.55 USD
Minimum Trading Value
7,800 JPY 50 USD
Market Cap
4.03B JPY 0.03B USD
Number of Trades
2,273
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
485
1-Year High Jan 8, 2025
8,347
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 7,282,100
Nov 28, 2025 0 7,137,100
Nov 21, 2025 0 7,237,500
Nov 14, 2025 0 7,900,900
Nov 7, 2025 0 8,001,000
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.